Clinical trials: Malignant Neoplasm of the Breast
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Breast Cancer, Hormone Receptor Positive Tumor
Dose EScalation Induction of EvERolimus
The BOLERO-2 study demonstrated a benefit for patients who received everolimus in addition to exemestane in patients who progressed during/after a non-steroidal aromatase inhibitor; Routine use of everolimus shows an high rate of…
- Trial name
- Desiree (NCT02387099)
- Testing
- 3 weeks Dose Induction of Everolimus, 3 weeks Conventional Everolimus Dosing, Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
- Where
- 14 sites in Germany
- Volunteers
- 156 people
- Sponsor
- GBG Forschungs GmbH
Body Mass Index Greater Than or Equal to 30, Malignant Breast Neoplasm
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
This trial studies the safety and how well negative pressure wound therapy works in healing the abdominal incision in obese patients undergoing free flap breast reconstruction surgery.
- Conditions
- Body Mass Index Greater Than or Equal to 30, Malignant Breast Neoplasm, Mammoplasty Patient, Obesity
- Trial name
- NCT04003038
- Testing
- Negative Pressure Wound Therapy, Wound Care Management
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
This phase I trial studies the side effects and best dose of entinostat and nivolumab when given together with ipilimumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma
- Trial name
- NCT02453620
- Testing
- Biopsy Procedure, Blood Sample, Bone Scan
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer, Metastatic Cancer
A Study of LY3023414 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
- Trial name
- NCT01655225
- Testing
- LY3023414, Midazolam, Fulvestrant
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
The purpose of this study is to determine whether biomarkers could be found to gain more insight in tumor characteristics in order to predict which patients will have a high chance of a long progression-free survival.
- Trial name
- NCT02109913
- Testing
- Everolimus plus Exemestane
- Where
- 28 sites in Netherlands
- Volunteers
- 175 people
- Sponsor
- Amsterdam UMC, location VUmc
Breast Neoplasms, Breast Cancer
An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
This study is intended to evaluate the safety, tolerability, and possible effectiveness of an investigational humanized monoclonal antibody (CAL) to the parathyroid hormone-related protein (PTHrP) when compared to zoledronic acid…
- Conditions
- Breast Neoplasms, Breast Cancer, Metastasis
- Trial name
- NCT00051779
- Testing
- CAL
- Where
- 38 sites in United States
- Sponsor
- Chugai Pharma USA
HER2-positive Breast Cancer, HER2 Low
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985
- Trial name
- NCT04602117
- Testing
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- QuantumLeap Healthcare Collaborative
Breast Carcinoma, Carcinoma of Unknown Primary
Cancer Genetic Testing in Ethnic Populations
This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk.
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Central Nervous System Carcinoma, Digestive System Carcinoma
- Trial name
- NCT04475640
- Testing
- Biospecimen Collection, Genetic Testing
- Where
- 2 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- Mayo Clinic
Malignant Pleural Disease, Mesothelioma
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
The purpose of this Phase I study is to test the safety of different doses of specially prepared immune cells (called "T cells") collected from blood.
- Conditions
- Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer
- Trial name
- NCT02414269
- Testing
- iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 113 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Breast Lesions, Dense Breast Tissue
Molecular Breast Imaging: A Novel Technology for Detection of Malignant Breast Lesions
Detection of breast cancer as early as possible is an ongoing imaging challenge.The purpose of the current study is to assess the clinical performance of the new scintigraphic technology, a dedicated breast gamma camera composed…
- Conditions
- Small Breast Lesions, Dense Breast Tissue, Discrepancy With Clinical Examination, Equivocal Mammographic, Sonographic or MRI Lesion
- Trial name
- NCT01004666
- Where
- Israel
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Breast Neoplasms
EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients
The purpose of this study is to assess the efficacy, safety and tolerability of a therapy with EndoTAG-1 + paclitaxel in combination and EndoTAG-1 alone as a rescue therapy for patients with relapsed or metastatic triple receptor…
- Trial name
- NCT00448305
- Testing
- EndoTAG-1 + paclitaxel, EndoTAG-1, Paclitaxel
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 143 people
- Sponsor
- MediGene
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Although randomized controlled trials (RCTs) provide evidence of efficacy, generalization of these results to patients in the real-world setting is challenging, given RCTs are conducted in highly selected patient populations.
- Trial name
- Treat ER+ight (NCT02753686)
- Testing
- Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
- Where
- 25 sites in Canada
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasm
Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer
Adapted physical activity (APA) was recognized as a non-drug therapy by the French Health Authority (HAS) in 2011. Very few studies have examined the efficiency of APA programs during the active phase of treatment in cancer…
- Trial name
- EMEAPA (NCT05949983)
- Testing
- APA Program, Recommendations for physical activity
- Where
- France
- Volunteers
- 866 people
- Sponsor
- University Hospital, Toulouse
Adenocarcinoma, Gastric, Neoplasm, Breast
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03368196
- Testing
- DS-8201a
- Where
- 2 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Radiotherapy, Adjuvant, Phyllodes Breast Tumor
Effects of Radiotherapy in Borderline and Malignant Phyllodes Tumors After R0 Resection
Breast phyllodes tumors (PT) are rare fibroepithelial neoplasms originating from stromal tissue and account for less than 1% of all breast tumors.
- Conditions
- Radiotherapy, Adjuvant, Phyllodes Breast Tumor, Prognosis
- Trial name
- NCT06780059
- Testing
- Adjuvant Radiotherapy, R0 resection
- Where
- 3 sites in China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
This is an open-label dose escalation study designed to evaluate the safety and pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in combination with standard therapies) in subjects with…
- Conditions
- Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Breast
- Trial name
- NCT02565758
- Testing
- ABBV-085
- Where
- 20 sites in United States, France and 1 more
- Volunteers
- 85 people
- Sponsor
- AbbVie
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Breast Neoplasm, Breast Cancer
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
Fear of cancer recurrence (FCR) is a highly prevalent, disruptive, and under-treated problem for breast cancer survivors. This randomized controlled trial will test the efficacy of group-based Acceptance and Commitment Therapy…
- Conditions
- Breast Neoplasm, Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
- Trial name
- NCT05364450
- Testing
- Enhanced Usual Care, Acceptance Commitment Therapy, Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 390 people
- Sponsor
- Indiana University